Sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors are a new type of antidiabetic drug that significantly reduce cardiovascular incidence and mortality in patients with T2DM.176, 177, 178. Here, SLC5A2 is linked to type 2 diabetes mellitus.